The International Society for CNS Clinical Trials and Methodology (ISCTM) held its annual conference this month at the Grand Hyatt in Washington D.C. The four day event covered everything in the field of CNS clinical trials, from neuroscience drug development to brain-gut axis in psychiatry and neurology. This year’s society meeting had an emphasis on the use of artificial intelligence and machine learning within the world of clinical trials. CiTrials CEO and conference attendee Debra Hoffmeyer, speaking on the subject, stated that the growing technology of AI could benefit the industry in numerous ways and optimize the process of drug development immensely. Hoffmeyer, new elect Chair of Membership Committee also sits on the Finance Committee of the ISCTM.
The International Society for CNS Clinical Trials and Methodology (ISCTM) is a multi-disciplinary independent organization, devoted to promoting advances that address strategic clinical, regulatory, methodological and policy challenges that arise in the development and use of CNS therapeutic agents. This work is accomplished through partnership with persons in academia, industry, government, policy-making, and the public. Focus in CNS in areas, schizophrenia, depression, bipolar, personality disorder, alzheimers and cognition clinical trials.